IonQ reported earnings on June 16 and fell 10.6% on the day — and the week after the print tells a story of short sellers quietly rebuilding positions into the weakness.
The borrow market has tightened since the earnings drop. Availability has fallen from 19.2% heading into the June 16 report to just 12.8% now — down 43% in a single week. That is a meaningful reversal: before the earnings-driven short unwind of late May and early June, availability had been near zero. Shorts spent the pre-earnings period covering, and some are now starting to re-enter. Short interest itself has barely moved week-on-week, down less than half a percent to 16% of the free float, but the directional drift in availability suggests the lending pool is being drawn on again. Cost to borrow remains low at under 1%, roughly half what it was a month ago, so the re-entry is not expensive — but supply is tightening. The ORTEX short score has drifted down to 67.6 from above 69 at the start of the month, a modest easing that reflects the net covering since mid-May but not yet a reversal of the post-earnings rebuild. Options are telling a quieter story: the put/call ratio is 1.07, essentially flat against its 20-day average of 1.08, with a z-score near zero — no unusual hedging demand in either direction.
The Street remains split, and the valuation is too stretched for the middle ground to feel comfortable. Bulls point to a mean price target of $67.64, roughly 24% above the current $54.69 close — with Rosenblatt maintaining a $100 target and Wedbush, which raised its target to $75 from $60 following the May earnings update, still at Outperform. JPMorgan is the cleaner read on bear sentiment: it rates the stock Neutral with a $50 target, below where it trades today. The formal consensus is Hold, with the analyst data roughly a month old. EPS surprise ranks in the bottom 2nd percentile of the ORTEX universe, and the 12-month forward EPS trend scores zero — the company remains deeply loss-making, with a negative P/E near -49 and EV/EBITDA at -59. The bear case is straightforward: IBM, Google, and Amazon are all pressing harder into quantum, and IonQ may not achieve commercial profitability before needing to tap markets again.
Insider activity adds a cautionary note. On June 11, the CEO sold 16,120 shares at $56.21, the CFO sold 6,272 shares at the same price, and the Executive Chairman and Company Secretary both sold smaller parcels in the same session. The 90-day net insider selling comes to roughly $1.84 million across the key leadership group. These are small as a percentage of the company, and all scored low on trade significance, but the pattern is consistent: IonQ executives have sold at every meaningful price recovery — at $34 in March, $50 in May, and now $56 in June. There has been no buying.
The earnings reaction history is short but relevant. The June 16 print produced a -10.6% one-day move. The prior earnings event in May showed only a -0.7% first-day reaction but recovered sharply, gaining 15% over the following five days. That asymmetry — a muted reaction followed by a rally — is worth noting given where the stock now sits. The next earnings date is August 5.
Among correlated peers, QUBT gained 2.5% on the week while IonQ fell 3.4%. SMCI dropped 5.1%, providing some sector-level drag context. The relative underperformance versus QUBT is modest but notable given both names trade on similar quantum-computing sentiment flows.
The question heading into August is whether the modest availability tightening this week is the start of a renewed short rebuild — or simply post-earnings noise before the next catalyst clears the picture.
See the live data behind this article on ORTEX.
Open IONQ on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
